Gilead Sees Promising Results in Study of Remdesivir Treatment for COVID-19 Patients: Report

Gilead  (GILD) - Get Report has seen promising results in a Chicago study of its antiviral drug remdesivir when used to treat COVID-19 patients, according to a published report Thursday.

The study involved 125 patients, of whom 113 had severe cases, STAT reported. Only two of the patients died, while most of the others were discharged within a week, according to the report, which cited a recording of a video discussion among researchers at the University of Chicago.

Similar trials are being run in many other locations.

The report quoted a 57-year-old factory worker who was admitted to the hospital on April 3 with shortness of breath and a fever of 104 degrees who agreed to participate in the study. He said his fever dropped almost immediately after the first treatment with remdesivir and that he recovered enough to leave the hospital by April 7.

Remdesivir is one of several treatments in various stages of development being tested for use against COVID-19. Researchers around the world are also pursuing a vaccine for the illness as well as improved and faster diagnostic testing.

The coronavirus pandemic has infected more than 2 million people around the world since emerging in China at the end of 2019. More than 145,000 people have died of COVID-19 including more than 34,000 in the United States.

Shares of Gilead jumped $10.87, or 14%, to $87.41 in after-hours trading. 

In regular action Thursday, gainers lead losers among coronavirus stocks.

Inovio  (INO) - Get Report shares rose 75 cents, or 10.5%, to $7.89. Inovio plans to begin clinical trials in April for its vaccine candidate.

Dynavax  (DVAX) - Get Report shares rose 28 cents, or 9.09%, to $3.36.
Dynavax is working with the Coalition for Epidemic Preparedness Innovations to give companies access to its adjuvant technology which can boost vaccine effectiveness.

Moderna  (MRNA) - Get Report shares rose $3.35, or 8.99%, to $40.60.
Moderna's COVID-19 vaccine candidate is expected to begin Phase 2 human trials in spring or early summer.

Among coronavirus stocks lagging Thursday, Vaxart  (VXRT) - Get Report shares fell 9 cents, or 4.41%, to $1.95.
Vaxart is in preclinical stages of development of an oral vaccine. It is planning Phase 1 clinical trials sometime in the second half of the year.

CytoDyn CYDY shares fell 9 cents, or 3.75%, to $2.31 in over-the-counter action Thursday.
CytoDyn is moving into Phase 2 trials of an experimental drug called leronlimab to treat respiratory complications in patients with COVID-19. 

Takeda  (TAK) - Get Report shares fell 22 cents, or 1.32%, to $16.51.
Takeda plans to test hyperimmune globulins for those at risk of being infected.

The SPDR S&P Biotech ETF  (XBI) - Get Report rose $2.28, or 2.7%, to $86.77.


Source link

You May Also Like

About the Author: Texas Covid

Leave a Reply

Your email address will not be published. Required fields are marked *


The maximum upload file size: 10 MB.
You can upload: image, audio, video, document, spreadsheet, interactive, other.
Links to YouTube, Facebook, Twitter and other services inserted in the comment text will be automatically embedded.

X